Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47755 

Contact Person: Angela Y Ng, Ph.D., MBA, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6200, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1715, nga@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Pregnancy, 

Placentation, and Neonatology. 

Date: November 9, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Gary Hunnicutt, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6164, 

MSC 7892, Bethesda, MD 20892, 301–435– 

0229, gary.hunnicutt@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 6, 2017. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22139 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

patent applications listed below may be 

obtained by emailing the indicated 

licensing contact at the National Heart, 

Lung, and Blood, Office of Technology 

Transfer and Development Office of 

Technology Transfer, 31 Center Drive 

Room 4A29, MSC2479, Bethesda, MD 

20892–2479; telephone: 301–402–5579. 

A signed Confidential Disclosure 

Agreement may be required to receive 

copies of the patent applications. 

SUPPLEMENTARY INFORMATION: This 

notice is in accordance with 35 U.S.C. 

209 and 37 CFR part 404 to achieve 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. A description of the 

technology follows. 

Small Interfering RNA Inhibition of 

Cannabanoid-1 Receptor (CB1R) for 

Treating Type 2 Diabetes 

Description of Technology: The 

invention pertains to the use of glucan 

encapsulated non-immunostimulatory 

small interfering RNAs (siRNAs) to treat 

type-2 diabetes. Endocannabinoids (EC) 

are lipid signaling molecules that act on 

the same cannabinoid receptors that 

recognize and mediate the effects of 

endo- and phytocannabanoids. EC 

receptor CB1R activation is implicated 

in the development of obesity and its 

metabolic consequences, including 

insulin resistance and type 2 diabetes. 

Beta-cell loss has been demonstrated in 

a Zucker diabetic fatty (ZDF) rat model 

of type-2 diabetes through CB1Rmediated activation of a macrophagemediated inflammatory response. 

Conversely, rats treated with a 

peripheral CB1R antagonist restores 

normoglycemia and preserves beta-cell 

function. Similar results are seen 

following selective in vivo knockdown 

of macrophage CB1R by daily treatment 

of ZDF rats with the instant D-glucanencapsulated CB1R Small interfering 

RNA (siRNA). Knock-down of CB1R 

with using glucan encapsulated siRNA 

may represent a new commecializable 

method of treating type-2 diabetes or 

preventing the progression of insulin 

resistance to overt diabetes. 

Potential Commercial Applications: 

Treatment of obesity, insulin resistance, 

and diabetes. 

Development Stage: In vivo data 

available. 

Inventors: George Kunos, Tony 

Jourdan (NIAAA), Michael Czech, 

Myriam Aouadi. 

Intellectual Property: HHS Reference 

No. E–103–2013/0, U.S. Provisional 

Patent Application 61/839,239 filed 

June 25, 2013, International Patent 

Application PCT/US2014/043924 filed 

June 24, 2014, European Patent 

Application 14818342.9 filed June 24, 

2014 and U.S. Patent Application 14/ 

900,951 filed June 24, 2014. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@nih.gov. 

Dated: October 5, 2017. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development. 

[FR Doc. 2017–22147 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Neurological Sciences 

Training Initial Review Group; NST–2 

Subcommittee. 

Date: October 23, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Crystal City, 2399 Jefferson 

Davis Highway, Arlington, VA 22202. 

Contact Person: Elizabeth Webber, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–1917, Webbere@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; R13 Review. 

Date: October 26, 2017. 

Time: 9:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Ernie Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–4056, lyonse@ninds.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; F32 and K22 Review. 

Date: November 2–3, 2017. 

Time: 8:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
47756 Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 

Place: The Westin Arlington Gateway, 801 

N. Glebe Road, Arlington, VA 22203. 

Contact Person: Jimok Kim, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, Jimok.kim@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Stroke Clinical Trials. 

Date: November 2, 2017. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Palomar, 2121 P Street NW., 

Washington, DC 20037. 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–6033, rajarams@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; R13 Review. 

Date: November 8, 2017. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Ernie Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–4056, lyonse@ninds.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Jointly Sponsored T32 

Review. 

Date: December 7–8, 2017. 

Time: 8:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites by Hilton 

Alexandria Old Town, 1900 Diagonal Road, 

Alexandria, VA 22314. 

Contact Person: Jimok Kim, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, Jimok.kim@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: October 6, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22142 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request; Specimen 

Resource Locator (NCI) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institutes of Health (NIH) has 

submitted to the Office of Management 

and Budget (OMB) a request for review 

and approval of the information 

collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30 days of October 13, 2017. 

ADDRESSES: Written comments and/or 

suggestions regarding the item(s) 

contained in this notice, especially 

regarding the estimated public burden 

and associated response time, should be 

directed to the: Office of Management 

and Budget, Office of Regulatory Affairs, 

OIRA_submission@omb.eop.gov or by 

fax to (202) 395–6974, Attention: Desk 

Officer for NIH. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: Joanne Demchok, 

Program Director, Cancer Diagnosis 

Program, Division of Cancer Treatment 

and Diagnosis, 9609 Medical Center 

Drive, Rockville, MD 20892 or call nontoll-free number (240) 276–5959 or 

Email your request, including your 

address to: peterjo@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on July 28, 2017 and allowed 

60 days for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. The 

National Cancer Institute (NCI), 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid OMB control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. 

Proposed Collection: Specimen 

Resource Locator, 0925–0703 

Reinstatement without Change, National 

Cancer Institute (NCI), National 

Institutes of Health (NIH). 

Need and Use of Information 

Collection: The availability of 

specimens and associated data is critical 

to increase our knowledge of cancer 

biology, and to translate important 

research discoveries to clinical 

application. The discovery and 

validation of cancer prevention markers 

require access, by researchers, to quality 

clinical biospecimens. In response, to 

this need, the National Cancer 

Institute’s (NCI) Cancer Diagnosis 

Program has developed, and is 

expanding, a searchable database: 

Specimen Resource Locator (SRL). The 

SRL allows scientists in the research 

community and the NCI to locate 

specimens needed for their research. 

The SRL will list all NCI supported 

repositories and their links. This 

administrative submission is an on-line 

form that will collect information to 

manage and improve a program and its 

resources for the use of all scientists. 

This submission does not involve any 

analysis. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

105. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden hours 

Private Sector .............................................................. Initial Request ........ 70 1 30/60 35 

State Government ....................................................... 70 1 30/60 35 

Federal Government .................................................... 60 1 30/60 30 

Private Sector .............................................................. Annual Update ....... 20 1 5/60 2 


asabaliauskas on DSKBBXCHB2PROD with NOTICES